Arch Venture Partners | GenomeWeb

Arch Venture Partners

The new company hopes to turn recombinant adeno-associated virus-based gene editing, which has minimal off-target effects, into new therapies.

The new firm will be based in the Boston area and is co-founded by MD Anderson Professor Raghu Kalluri and Broad Institute Director Eric Lander.

Leroy Hood called the bill short-sighted and said that over the long-term it could potentially reduce the attractiveness of starting up companies in the Seattle area.

The newly formed Decode Genetics Ehf will continue all of Decode's human genetics operations and brand products and services. Meantime, the publicly traded entity known as Decode Genetics expects to be liquidated.

Saga Investments has financial backing from Arch Venture Partners and Polaris Venture Partners, both of which had previously invested in Decode.

Lycera, which is developing drugs for autoimmune diseases, will use the cash to advance through Phase II proof-of-concept studies a drug based on University of Michigan research, and into Phase I trials a second candidate based on research conducted at New York University.

The deal brings to six the number of academic institutions from which Fate has licensed IP related to using small molecules to induce pluripotency in stem cells for therapeutic effect, drug discovery, and matched cell-replacement therapies.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.